LudovicRibes

Associate

Paris + 33.1.56.59.38.70

Ludovic Ribes practices in the area of general corporate and securities law, focusing on capital markets and public M&A deals. He advises companies and financial institutions on an array of capital markets transactions including equity and debt offerings, public and private placements, initial public offerings (IPOs), mergers and tender offerings, as well as on issuers' reporting requirements and governance matters.

Prior to joining Jones Day in 2024, Ludovic practiced at a Paris-based law firm where he assisted clients with stock market transactions including share capital increases, public offerings and private placements, reverse stock split, distressed M&A acquisitions, implementation of employee incentive plans, issuances of preferred shares, convertible and nonconvertible notes, warrants, and mixed securities. He also advised clients on their negotiation of shareholders' agreements and share purchase agreements and regularly counseled clients on governance-related matters and periodic and ongoing reporting obligations for issuers and management.

Experiência

  • Sanofi to separate its consumer healthcare business, OpellaJones Day is acting as securities law counsel to Sanofi in the separation of Opella, its consumer healthcare business, and the announced sale of a 50% controlling stake.
  • Valneva raises €61 million in accelerated bookbuilding offeringJones Day advised Valneva SE, a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs, in connection with its capital €61 million private placement through an accelerated bookbuilding process.
  • Tender offer for Eurobio Scientific launched by NextStage AM and IK PartnersJones Day is advising Eurobio Scientific SA in the tender offer launched by a consortium led by the management of Eurobio Scientific and funds managed by NextStage AM and IK Investment Partners, at a price of €25.3 per share increased by €1.25 per share if the threshold of 90% of Eurobio Scientific's capital and voting rights is reached, representing a maximum amount of approximately €161 million and valuating Eurobio Scientific at approximately €270 million.